Intellectual Property India Publishes Patent Application for 'Coagulation Factor Xi-Modulating Compositions And Methods Of Use Thereof' Filed by Adarx Pharmaceuticals, Inc.

MUMBAI, India, March 14 -- Intellectual Property India has published a patent application (202617020041 A) filed by Adarx Pharmaceuticals, Inc., San Diego, on Feb. 20, for 'coagulation factor xi-modulating compositions and methods of use thereof.'

Inventor(s) include Li, Zhen; Zhu, Rui; Macleod, Alan Robert; and Fultz, Kimberly.

The application for the patent was published on March 13, under issue no. 11/2026.

According to the abstract released by the Intellectual Property India: "Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of Coagulation Factor XI (FXI). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of FXI mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of FXI protein in a cell or animal."

The patent application was internationally filed on July 19, 2024, under International application No.PCT/US2024/038771.

Disclaimer: Curated by HT Syndication.